NCT00038064View on ClinicalTrials.gov

Anemia in Patients With a Non-Myeloid Malignancy

PHASE3CompletedINTERVENTIONAL
Enrollment

707

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

April 30, 2004

Conditions
NeoplasmsAnemia
Interventions
DRUG

Darbepoetin alfa

Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.

DRUG

rHuEPO

150 IU/kg TIW

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY